Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

66.95 +2.76 (+4.30%)
Streaming Delayed Price Updated: 3:50 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
From Guardant Health, Inc.
Via Business Wire
FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
From Guardant Health, Inc.
Via Business Wire
Alex M. Azar II Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Host Investor Day on September 24, 2025
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+
From Guardant Health, Inc.
Via Business Wire
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer
From Guardant Health, Inc.
Via Business Wire
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025
From Guardant Health, Inc.
Via Business Wire
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
From Guardant Health, Inc.
Via Business Wire
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
From Guardant Health, Inc.
Via Business Wire
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
From Guardant Health, Inc.
Via Business Wire
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.